John Paul Fruehauf MD

Oncology•Orange, CA

Genitourinary Oncology, Hematologic Oncology, Melanoma, Sarcoma

Professor of Medicine, UC Irvine

Join to View Full Profile

UCI Medical Center101 The City Drive SouthOrange, CA 92868
Phone+1 714-456-8978
Fax+1 855-211-3729

Education & Training

National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1987 - 1990
University of California (Irvine)Internship, Internal Medicine, 1986 - 1987
Rush Medical College of Rush University Medical CenterClass of 1985

Certifications & Licensure

TX State Medical License 2022 - 2027
CA State Medical License 1986 - 2026
HI State Medical License 2023 - 2026
IL State Medical License 2023 - 2026
MD State Medical License 1987 - 2026
AZ State Medical License 2022 - 2025
GA State Medical License 2021 - 2025
KY State Medical License 2022 - 2025
WA State Medical License 2022 - 2025
NV State Medical License 2022 - 2023
American Board of Internal Medicine Medical Oncology
Join now to see all

Awards, Honors, & Recognition

Top Doctors:LA Area Castle Connolly, 2013
Top Doctors:San Diego Area Castle Connolly, 2013
Top Doctors:Southern California Castle Connolly, 2012
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Disulfiram in Patients With Metastatic Melanoma Start of enrollment: 2002 Jan 01
Completed
Phase 1, Phase 2
Docetaxel and Vinorelbine Plus Sargramostim in Metastatic Malignant Melanoma Start of enrollment: 2003 Apr 01
Completed
Phase 2
Cisplatin Induction With Paclitaxel Consolidation for Stage III-IV Epithelial Ovarian and Primary Peritoneal Cancer Start of enrollment: 2005 Sep 01
Completed
Phase 2
Disulfiram Plus Arsenic Trioxide In Patients With Metastatic Melanoma and at Least One Prior Systemic Therapy Start of enrollment: 2006 Sep 01
Terminated
Phase 1
Neoadjuvant Docetaxel on Newly Diagnosed Intermediate and High Grade Cancer of the Prostate Start of enrollment: 2009 Jan 01
Withdrawn
Phase 2
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Start of enrollment: 2009 Jul 15
Completed
Phase 3
Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma Start of enrollment: 2010 Aug 01
Completed
Phase 2
Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma Start of enrollment: 2011 Dec 01
Completed
Phase 2
Docetaxel Plus Lycopene in Castration Resistant, Chemotherapy-Naïve Prostate Cancer Patients Start of enrollment: 2010 Dec 01
Completed
Phase 2
Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma Start of enrollment: 2013 Sep 12
COMPLETED
PHASE3
Evaluation of Oxaliplatin and Gemcitabine in Patients With Metastatic Bladder Cancer Start of enrollment: 2005 Jan 20
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

1 citations
Southwest Oncology Group S0826: A phase 2 trial of SCH 727965 (NSC 727135, dinaciclib) in patients with stage IV melanoma.
Christopher D Lao, James Moon, Vincent T Ma, John P Fruehauf, Lawrence E Flaherty
Cancer. 2025-01-01
14 citations
A phase II study of docetaxel plus lycopene in metastatic castrate resistant prostate cancer.
Eric Zhuang, Edward Uchio, Michael B. Lilly, Xiaolin Zi, John P. Fruehauf
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 2021-09-24
31 citations
HIF Inactivation of p53 in Ovarian Cancer Can Be Reversed by Topotecan, Restoring Cisplatin and Paclitaxel Sensitivity
Basmina Parmakhtiar, Robert A. Burger, Jai-Hyun Kim, John P. Fruehauf
Molecular Cancer Research. 2019-05-14

Grant Support

Novel Biologic Markers Of Treatment Resistance In Locally Advanced Cervical CarciNational Cancer Institute2011–2012
Translational Oncology ProgramNational Cancer Institute2009–2011
Genomics Screening For Antiangiogenesis DrugsNational Cancer Institute2002
Core--Clinical Trials Protocol ReviewNational Cancer Institute2002
Development Of An MDR-1 Resistance-Reversal AssayNational Cancer Institute1993
Development Of A Therapeutic TNF Degradation ProductNational Cancer Institute1993